The effects of a Chinese medicinal suppository (Vitalliver) on insulin-like growth factor 1 and homocysteine in patients with hepatitis B infection.

2.50
Hdl Handle:
http://hdl.handle.net/2436/15834
Title:
The effects of a Chinese medicinal suppository (Vitalliver) on insulin-like growth factor 1 and homocysteine in patients with hepatitis B infection.
Authors:
Chui, Siu-Hon; Chan, Kelvin C.; Chui, Albert K. K.; Shek, L.S.; Wong, Ricky N. S.
Abstract:
The liver is the major organ for the metabolism of homocysteine (Hcy) and production of insulin-like growth factor 1 (IGF-1). Hcy metabolism and IGF-1 synthesis may be impaired in chronic liver diseases. The study investigated the regulatory effect of a Chinese herbal suppository, Vitalliver, on Hcy and IGF-1, as well as their relationship in patients with hepatitis B infection. Forty patients with chronic hepatitis B virus (HBV) infection without cirrhosis, 25 males and 15 females, were observed for changes in Hcy and IGF-1 after the administration of Vitalliver (one nightly) for a period of 3 months. Serum levels of Hcy, IGF-1 and IGFBP-3 were measured at baseline, and at 1 month and 3 months after treatment. Vitalliver reduced Hcy levels significantly (p = 0.001) from 9.7 +/- 2.8 to 9.0 +/- 2.1 micromol/L after treatment of 3 months. Furthermore, the IGF-1 levels increased significantly (p < 0.001) from 170.2 +/- 81.8 to 212.8 +/- 80.9 ng/mL at 1 month and 187.5 +/- 72.3 ng/mL at 3 months (p = 0.001) after treatment. In conclusion, it is speculated Vitalliver may have a self-regulatory effect on the release of IGF-1 in HBV patients without liver cirrhosis.
Citation:
Phytotherapy Research, 19(8): 674-678
Publisher:
Wiley InterScience
Issue Date:
2005
URI:
http://hdl.handle.net/2436/15834
DOI:
10.1002/ptr.1726
PubMed ID:
16177969
Additional Links:
http://www3.interscience.wiley.com/journal/112094128/abstract
Type:
Article
Language:
en
Description:
Metadata only
ISSN:
0951-418X
Appears in Collections:
Pharmacy and Natural Products Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorChui, Siu-Hon-
dc.contributor.authorChan, Kelvin C.-
dc.contributor.authorChui, Albert K. K.-
dc.contributor.authorShek, L.S.-
dc.contributor.authorWong, Ricky N. S.-
dc.date.accessioned2008-01-08T15:12:12Z-
dc.date.available2008-01-08T15:12:12Z-
dc.date.issued2005-
dc.identifier.citationPhytotherapy Research, 19(8): 674-678en
dc.identifier.issn0951-418X-
dc.identifier.pmid16177969-
dc.identifier.doi10.1002/ptr.1726-
dc.identifier.urihttp://hdl.handle.net/2436/15834-
dc.descriptionMetadata onlyen
dc.description.abstractThe liver is the major organ for the metabolism of homocysteine (Hcy) and production of insulin-like growth factor 1 (IGF-1). Hcy metabolism and IGF-1 synthesis may be impaired in chronic liver diseases. The study investigated the regulatory effect of a Chinese herbal suppository, Vitalliver, on Hcy and IGF-1, as well as their relationship in patients with hepatitis B infection. Forty patients with chronic hepatitis B virus (HBV) infection without cirrhosis, 25 males and 15 females, were observed for changes in Hcy and IGF-1 after the administration of Vitalliver (one nightly) for a period of 3 months. Serum levels of Hcy, IGF-1 and IGFBP-3 were measured at baseline, and at 1 month and 3 months after treatment. Vitalliver reduced Hcy levels significantly (p = 0.001) from 9.7 +/- 2.8 to 9.0 +/- 2.1 micromol/L after treatment of 3 months. Furthermore, the IGF-1 levels increased significantly (p < 0.001) from 170.2 +/- 81.8 to 212.8 +/- 80.9 ng/mL at 1 month and 187.5 +/- 72.3 ng/mL at 3 months (p = 0.001) after treatment. In conclusion, it is speculated Vitalliver may have a self-regulatory effect on the release of IGF-1 in HBV patients without liver cirrhosis.en
dc.language.isoenen
dc.publisherWiley InterScienceen
dc.relation.urlhttp://www3.interscience.wiley.com/journal/112094128/abstracten
dc.subjectHomocysteineen
dc.subjectVitalliveren
dc.subjectHepatitis Ben
dc.titleThe effects of a Chinese medicinal suppository (Vitalliver) on insulin-like growth factor 1 and homocysteine in patients with hepatitis B infection.en
dc.typeArticleen
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.